News|Articles|February 19, 2026
From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle
Author(s)CoverMyMeds
Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.
What you’ll learn:
- Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively.
- Learn how data-driven insights and affordability solutions can help biopharma support providers and pharmacists at every stage.
- Understand the strategic role of lifecycle planning in improving medication access, reducing industry fragmentation and enhancing patient outcomes.
Trending on PharmExec
1
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
2
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
3
Pharmaceutical Executive Daily: FDA Approves Simtriyo
4
Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies
5